Biomolecules and Materials

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-COV2) (B.1.2) Summary ARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.2): hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for SARS-CoV-2 strain B.1.2 The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Formulation & Storage: Store at -80°C. Notes & Usage Guidelines: Spike Mutations: Spike D614G, Spike E484K, Spike G446V, Spike Y453F Size: 25 X 200 µL ~100 wells-96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Intended for research use only, not for human, therapeutic, or diagnostic applications. Overview PRODUCT NAME SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.2) PRODUCT TARGET SARS-CoV-2 Virus-like particle PRODUCT ABBREVIATION SARS-CoV-2 VLP PATHOGEN STRAIN (B.1.2) TARGET PATHOGEN SARS-CoV-2 Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-Cov2) Lambda (C.37) Summary SARS-CoV-2, Virus Like Particles (Ha-CoV2) Lambda (C.37) : hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for strain Lambda (C.37) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Formulation & Storage: Available upon request Store at -80°C. Notes & Usage Guidelines: Spike Mutations: Spike G75V, Spike T76I, Spike R246N, Spike del247-253, Spike L452Q, Spike F490S, Spike D614G, Spike T859N Size: 25 X 200 µL ~100 wells-96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Overview PRODUCT NAME SARS-CoV-2, Virus Like Particles (Ha-CoV2) Lambda (C.37) PRODUCT TARGET SARS-CoV-2 Virus-like particle PRODUCT ABBREVIATION SARS-CoV-2 VLP PATHOGEN STRAIN Lambda (C.37) TARGET PATHOGEN SARS-CoV-2 Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-Cov2) Mu (B.1.621) Summary SARS-CoV-2, Virus Like Particles (Ha-CoV2) Mu (B.1.621): hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for strain Mu (B.1.621) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Formulation & Storage: Store at -80°C. Notes & Usage Guidelines: Spike Mutations: Spike T95I, Spike Y144S, Spike Y145N, Spike R346K, Spike E484K, Spike N501Y, Spike D614G, Spike P681H, Spike D950N Size: 25 X 200 µL ~100 wells-96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Intended for research use only, not for human, therapeutic, or diagnostic applications. Overview PRODUCT NAME SARS-CoV-2, Virus Like Particles (Ha-CoV2) Mu (B.1.621) PRODUCT TARGET SARS-CoV-2 Virus-like particle PRODUCT ABBREVIATION SARS-CoV-2 VLP PATHOGEN STRAIN Mu (B.1.621) TARGET PATHOGEN SARS-CoV-2 Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-Cov2) Delta (B.1.617.2) Summary SARS-CoV-2, Virus Like Particles (Ha-CoV2) Delta (B.1.617.2): hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for strain Delta (B.1.617.2) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Formulation & Storage: Store at -80°C. Notes & Usage Guidelines: Spike Mutations: Spike T19R, Spike del157-158, Spike L452R, Spike T478K, Spike D614G, Spike P681R, Spike D950N Size: 25 X 200 µL ~100 wells-96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Intended for research use only, not for human, therapeutic, or diagnostic applications. Overview PRODUCT NAME SARS-CoV-2, Virus Like Particles (Ha-CoV2) Delta (B.1.617.2) PRODUCT TARGET SARS-CoV-2 Virus-like particle PRODUCT ABBREVIATION SARS-CoV-2 VLP PATHOGEN STRAIN Delta (B.1.617.2) TARGET PATHOGEN SARS-CoV-2 Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-COV2) Eta (B.1.525) Summary SARS-CoV-2, Virus Like Particles (Ha-CoV2) Eta (B.1.525) : hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for strain Eta (B.1.525) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Formulation & Storage: Available upon request Store at -80°C. Notes & Usage Guidelines: Spike Mutations: Spike A67V, Spike D614G, Spike E484K, Spike F888L, Spike H69del, Spike Q52R, Spike Q677H, Spike V70del, Spike Y144del Size: 25 X 200 µL ~100 wells-96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Intended for research use only, not for human, therapeutic, or diagnostic applications. Overview PRODUCT NAME SARS-CoV-2, Virus Like Particles (Ha-CoV2) Eta (B.1.525) PRODUCT TARGET SARS-CoV-2 Virus-like particle PRODUCT ABBREVIATION SARS-CoV-2 VLP PATHOGEN STRAIN Eta (B.1.525) TARGET PATHOGEN SARS-CoV-2 Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices SARS-COV-2 Virus Like Particles (Ha-Cov2) Delta Plus (Ay.2) Summary SARS-CoV-2, Virus Like Particles (Ha-CoV2) Delta Plus (AY.2): hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for strain Delta Plus (AY.2) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Formulation & Storage: Available upon request Store at -80°C. Notes & Usage Guidelines: Spike Mutations: Spike T19R, Spike V70F, Spiked del157-158, Spike A222V, Spike K417N, Spike L452R, Spike T478K, Spike D614G, Spike P681R, Spike D950N Size: 25 X 200 µL ~100 wells-96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Intended for research use only, not for human, therapeutic, or diagnostic applications. Overview PRODUCT NAME SARS-CoV-2 Virus Like Particles (Ha-CoV2) Delta Plus (AY.2) PRODUCT TARGET SARS-CoV-2 Virus-like particle PRODUCT ABBREVIATION SARS-CoV-2 VLP PATHOGEN STRAIN Delta Plus (AY.2) TARGET PATHOGEN SARS-CoV-2 Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-Cov2) Delta Plus (Ay4.2) Summary SARS-CoV-2, Virus Like Particles (Ha-CoV2) Delta Plus (AY4.2): hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for strain Delta Plus (AY4.2) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Notes & Usage Guidelines: Spike Mutations: Spike T19R, Spike T95I, Spike G142D, Spike Y145H, Spike E156G, Spike del157-158, Spike A222V, Spike L452R, Spike T478K, Spike D614G, Spike P681R, Spike D950N Size: 25 X 200 µL ~100 wells-96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Intended for research use only, not for human, therapeutic, or diagnostic applications. Overview PRODUCT NAME SARS-CoV-2, Virus Like Particles (Ha-CoV2) Delta Plus (AY4.2) PRODUCT TARGET SARS-CoV-2 Virus-like particle PRODUCT ABBREVIATION SARS-CoV-2 VLP PATHOGEN STRAIN Delta Plus (AY4.2) TARGET PATHOGEN SARS-CoV-2 Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-COV2) (B.1.494) Summary SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.494): hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for strain B.1.494 The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Formulation & Storage: Store at -80°C. Notes & Usage Guidelines: Spike Mutations: Spike A262S, Spike D614G, Spike D796Y, Spike H49Y, Spike L452R, Spike N501Y, Spike P681R, Spike Q613H Size: 25 X 200 µL ~100 wells-96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Intended for research use only, not for human, therapeutic, or diagnostic applications. Overview PRODUCT NAME SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.494) PRODUCT TARGET SARS-CoV-2 Virus-like particle PRODUCT ABBREVIATION SARS-CoV-2 VLP PATHOGEN STRAIN (B.1.494) TARGET PATHOGEN SARS-CoV-2 Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-Cov2) Epsilon (B.1.427-429) Summary SARS-CoV-2, Virus Like Particles (Ha-CoV2) Epsilon (B.1.427-429) : hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for strain Epsilon (B.1.427-429) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Formulation & Storage: Store at -80°C. Notes & Usage Guidelines: Spike Mutations: Spike D614G, Spike E484K, Spike L452R, Spike S13I, Spike W152C Size: 25 X 200 µL ~100 wells-96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Intended for research use only, not for human, therapeutic, or diagnostic applications Overview PRODUCT NAME SARS-CoV-2, Virus Like Particles (Ha-CoV2) Epsilon (B.1.427-429) PRODUCT TARGET SARS-CoV-2 Virus-like particle PRODUCT ABBREVIATION SARS-CoV-2 VLP PATHOGEN STRAIN Epsilon (B.1.427-429) TARGET PATHOGEN SARS-CoV-2 Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-COV2) Epsilon (B.1.429) Summary SARS-CoV-2, Virus Like Particles (Ha-CoV2) Epsilon (B.1.429): hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for strain Epsilon (B.1.429) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Formulation & Storage: Store at -80°C. Notes & Usage Guidelines: Spike Mutations: Spike A222V, Spike D614G, Spike L452R, Spike S13I, Spike W152C Size: 25 X 200 µL ~100 wells-96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Intended for research use only, not for human, therapeutic, or diagnostic applications. Overview PRODUCT NAME SARS-CoV-2, Virus Like Particles (Ha-CoV2) Epsilon (B.1.429) PRODUCT TARGET SARS-CoV-2 Virus-like particle PRODUCT ABBREVIATION SARS-CoV-2 VLP PATHOGEN STRAIN Epsilon (B.1.429) TARGET PATHOGEN SARS-CoV-2 Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-COV2) (B.1.351) Summary SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.351): hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for strain B.1.351 The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Formulation & Storage: Store at -80°C. Notes & Usage Guidelines: Spike Mutations: Spike A243del, Spike A701V, Spike D80A, Spike D215G, Spike D614G, Spike E484K, Spike K417N, Spike L242del, Spike L244del, Spike N501Y Size: 25 X 200 µL ~100 wells-96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Intended for research use only, not for human, therapeutic, or diagnostic applications. Overview PRODUCT NAME SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.351) PRODUCT TARGET SARS-CoV-2 Virus-like particle PRODUCT ABBREVIATION SARS-CoV-2 VLP PATHOGEN STRAIN Beta (B.1.351) TARGET PATHOGEN SARS-CoV-2 Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-COV2) Gamma (P.1) Summary SARS-CoV-2, Virus Like Particles (Ha-CoV2) Gamma (P.1): hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for strain Gamma (P.1) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Formulation & Storage: Store at -80°C. Notes & Usage Guidelines: Spike Mutations: Spike D138Y, Spike D614G, Spike E484K, Spike H655Y, Spike K417T, Spike L18F, Spike N501Y, Spike P26S, Spike R190S, Spike T20N, Spike T1027I, Spike V1176F Size: 25 X 200 µL ~100 wells-96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Intended for research use only, not for human, therapeutic, or diagnostic applications. Overview PRODUCT NAME SARS-CoV-2, Virus Like Particles (Ha-CoV2) Gamma (P.1) PRODUCT TARGET SARS-CoV-2 Virus-like particle PRODUCT ABBREVIATION SARS-CoV-2 VLP PATHOGEN STRAIN Gamma (P.1) TARGET PATHOGEN SARS-CoV-2 Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-COV2) Kappa (B.1.617.1) Summary SARS-CoV-2, Virus Like Particles (Ha-CoV2) Kappa (B.1.617.1): hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for strain Kappa (B.1.617.1) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Formulation & Storage: Store at -80°C. Notes & Usage Guidelines: Spike Mutations: Spike E154K, Spike L452R, Spike E484Q, Spike D614G, Spike P681R, Spike Q1071H Size: 25 X 200 µL ~100 wells-96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Overview PRODUCT NAME SARS-CoV-2, Virus Like Particles (Ha-CoV2) Kappa (B.1.617.1) PRODUCT TARGET SARS-CoV-2 Virus-like particle PRODUCT ABBREVIATION SARS-CoV-2 VLP PATHOGEN STRAIN Kappa (B.1.617.1) TARGET PATHOGEN SARS-CoV-2 Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-COV2) (B.1.258) Summary SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.258): hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for strain B.1.258 The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Formulation & Storage: Store at -80°C. Notes & Usage Guidelines: Spike Mutations: Spike D614G, Spike H69del, Spike N439K, Spike V70del Size: 25 X 200 µL ~100 wells-96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Intended for research use only, not for human, therapeutic, or diagnostic applications. Overview PRODUCT NAME SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.258) PRODUCT TARGET SARS-CoV-2 Virus-like particle PRODUCT ABBREVIATION SARS-CoV-2 VLP PATHOGEN STRAIN (B.1.258) TARGET PATHOGEN SARS-CoV-2 Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-Cov2) (Ba.4.6 ) Summary SARS-CoV-2, Virus Like Particles (Ha-CoV2) (BA.4.6 ): hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for BA.4.6 strain The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Notes & Usage Guidelines: Spike Mutations: Spike T19I, Spike L24S, Spike del25-27, Spike del69-70, Spike G142D, Spike V213G, Spike G339D, Spike R346T, Spike S371F, Spike S373P, Spike S375F, Spike T376A, Spike D405N, Spike R408S, Spike K417N, Spike N440K, Spike L452R, Spike S477N, Spike T478K, Spike E484A, Spike F486V, Spike Q498R, Spike N501Y, Spike Y505H, Spike D614G, Spike H655Y, Spike N658S, Spike N679K, Spike P681H, Spike N764K, Spike D796Y, Spike Q954H, Spike N969K Size: 25 X 200 µL ~100 wells-96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Overview PRODUCT NAME SARS-CoV-2, Virus Like Particles (Ha-CoV2) (BA.4.6 ) PRODUCT TARGET SARS-CoV-2 Virus-like particle PRODUCT ABBREVIATION SARS-CoV-2 VLP PATHOGEN STRAIN BA.4.6 TARGET PATHOGEN SARS-CoV-2 Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-Cov2) (Bq.1.1) Summary SARS-CoV-2, Virus Like Particles (Ha-CoV2) (BQ.1.1): hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for BQ.1.1 strain The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Notes & Usage Guidelines: Spike Mutations: Spike T19I, Spike L24S, Spike del25-27, Spike del69-70, Spike G142D, Spike V213G, Spike G339D, Spike R346T, Spike S371F, Spike S373P,Spike S375F, Spike T376A, Spike D405N, Spike R408S, Spike K417N, Spike N440K, Spike K444T, Spike L452R, Spike N460K, Spike S477N, Spike T478K, Spike E484A, Spike F486V, Spike Q498R, Spike N501Y, Spike Y505H, Spike D614G, Spike H655Y, Spike N679K, Spike P681H, Spike N764K, Spike D796Y, Spike Q954H, Spike N969K Size: 25 X 200 µL ~100 wells-96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Intended for research use only, not for human, therapeutic, or diagnostic applications Overview PRODUCT NAME SARS-CoV-2, Virus Like Particles (Ha-CoV2) (BQ.1.1) PRODUCT TARGET SARS-CoV-2 Virus-like particle PRODUCT ABBREVIATION SARS-CoV-2 VLP PATHOGEN STRAIN BQ.1.1 TARGET PATHOGEN SARS-CoV-2 Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-Cov2) (XBB.1.9.1) Summary SARS-CoV-2, Virus Like Particles (Ha-CoV2) (XBB.1.9.1): hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for XBB.1.9.1 strain. The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike T19I, Spike L24S, Spike Del25-27, Spike V83A, Spike G142D, Spike Del144-144, Spike H146Q, Spike Q183E, Spike V213E, Spike G339H, Spike R346T, Spike L368I, Spike S371F, Spike S373P, Spike S375F, Spike T376A, Spike D405N, Spike R408S, Spike K417N, Spike N440K, Spike V445P, Spike G446S, Spike N460K, Spike S477N, Spike T478K, Spike E484A, Spike F486P, Spike F490S, Spike Q498R, Spike N501Y, Spike Y505H, Spike D614G, Spike H655Y, Spike N679K, Spike P681H, Spike N764K, Spike D796Y, Spike Q954H, Spike N969K Size: 25 X 200 µL ~100 wells-96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Intended for research use only, not for human, therapeutic, or diagnostic applications. Overview PRODUCT NAME SARS-CoV-2, Virus Like Particles (Ha-CoV2) (XBB.1.9.1) PRODUCT TARGET SARS-CoV-2 Virus-like particle PRODUCT ABBREVIATION SARS-CoV-2 VLP PATHOGEN STRAIN XBB.1.9.1 TARGET PATHOGEN SARS-CoV-2 Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-Cov2) (XBB.1) Summary SARS-CoV-2, Virus Like Particles (Ha-CoV2) (XBB.1): hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for XBB.1 strain. The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike T19I, Spike L24S, Spike del25-27, Spike V83A, Spike G142D,Spike del144-144, Spike H146Q, Spike Q183E, Spike V213E, Spike G252V, Spike G339H, Spike R346T, Spike L368I, Spike S371F, Spike S373P, Spike S375F, Spike T376A, Spike D405N, Spike R408S, Spike K417N,Spike N440K, Spike V445P, Spike G446S, Spike N460K, Spike S477N, Spike T478K, Spike E484A, Spike F486S, Spike F490S, Spike Q498R, Spike N501Y, Spike Y505H, Spike D614G, Spike H655Y, Spike N679K, Spike P681H, Spike N764K, Spike D796Y, Spike Q954H, Spike N969K Size: 25 X 200 µL ~100 wells-96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Intended for research use only, not for human, therapeutic, or diagnostic applications Overview PRODUCT NAME SARS-CoV-2, Virus Like Particles (Ha-CoV2) (XBB.1) PRODUCT TARGET SARS-CoV-2 Virus-like particle PRODUCT ABBREVIATION SARS-CoV-2 VLP PATHOGEN STRAIN XBB.1 TARGET PATHOGEN SARS-CoV-2 Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices Middle Eastern Respiratory Syndrome Corona Virus 2 (MERS-COV-2) Virus Like Particle, Wild Type Summary Middle Eastern Respiratory Syndrome Corona Virus 2 (MERS-CoV-2) Virus Like Particle, Wild Type: hybrid alpha-pseudovirus for MERS-CoV-2 (Ha-MERS-CoV-2) for Wild Type strain. The hybrid alpha-pseudovirus for MERS-CoV-2 (Ha-MERSCoV-2) is a newly developed MARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)pseudoviruses, Ha-MERS-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of MERS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Formulation & Storage: Store at -80°C. Notes & Usage Guidelines: Size: •60X concentrated 5 x 100 µL •1x Conc. 25 x 200uL (~100 wells) Reporter: Available with Firefly luciferase, GFP, or RFP Applications: • Screening and quantification of anti-coronavirusneutralizing antibodies • Anti-coronavirus drug screening • Quantification of viral mutants’ infectivity • Identification of host co-factors and restriction factors of coronaviruses Intended for research use only, not for human, therapeutic, or diagnostic applications. Overview PRODUCT NAME Middle Eastern Respiratory Syndrome Corona Virus 2 (MERS-CoV-2) Virus Like Particle, Wild Type PRODUCT TARGET MERS-CoV Virus-like particle PRODUCT ABBREVIATION MERS-CoV VLP PATHOGEN STRAIN Wild Type TARGET PATHOGEN MERS-CoV Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-Cov2) (Bq.1) Summary SARS-CoV-2, Virus Like Particles (Ha-CoV2) (BQ.1): hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for BQ.1 strain The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle Notes & Usage Guidelines: Spike Mutations: Spike T19I, Spike L24S, Spike del25-27, Spike del69-70, Spike G142D, Spike V213G, Spike G339D, Spike S371F, Spike S373P,Spike S375F, Spike T376A, Spike D405N, Spike R408S, Spike K417N, Spike N440K, Spike K444T, Spike L452R, Spike N460K, Spike S477N, Spike T478K, Spike E484A, Spike F486V, Spike Q498R, Spike N501Y, Spike Y505H, Spike D614G, Spike H655Y, Spike N679K, Spike P681H, Spike N764K, Spike D796Y, Spike Q954H, Spike N969KSpike P681H, Spike N764K, Spike D796Y, Spike Q954H, Spike N969K Size: 25 X 200 µL ~100 wells-96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Overview PRODUCT NAME SARS-CoV-2, Virus Like Particles (Ha-CoV2) (BQ.1) PRODUCT TARGET SARS-CoV-2 Virus-like particle PRODUCT ABBREVIATION SARS-CoV-2 VLP PATHOGEN STRAIN BQ.1 TARGET PATHOGEN SARS-CoV-2 Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices Ebola Virus Like Particles (Ha-EBOV) Sudan (Genebank: YP_138523.1) Summary Ebola Virus like particles (HA-EBOV) Sudan (Genebank: YP_138523.1): A novel rapid hybrid alpha-pseudovirus for Ebolaviruses (EBOV) (HA-EBOV) that are available for your initial testing from the Sudan Ebola strain (Genebank: YP_138523.1) These pseudoviruses are BSL2 safe and ready to use for studying viral entry. HAEBOV particles are pseudoviruses assembled from the structural proteins of the filovirus glycoprotein (GP), VP40 matrix protein, and the Nucleoprotein (NP) and package an alphaviral vector for reporter gene expression. The alpha-pseudoviruses are single-cycle viruses with self-replicating RNA for rapid quantification of neutralizing antibodies and entry-inhibiting drugs. Formulation & Storage: Store at -80°C. Notes & Usage Guidelines: Size: 1X concentrated 25 x 200 µL ~100 wells-96 well plate Reporter: Available with Firefly luciferase, GFP, or RFP This Ebola Virus like particles is intended for research use only, not for human, therapeutic, or diagnostic applications. Certificate of analysis: A hardcopy of datasheet is sent along with the products. Please refer to it for detailed information. Overview PRODUCT NAME Ebola Virus like particles (HA-EBOV) Sudan (Genebank: YP_138523.1) PRODUCT TARGET EBOV Virus like particle PRODUCT ABBREVIATION EBOV VLP PATHOGEN STRAIN Sudan EBOV MT583348.1 TARGET PATHOGEN Ebola Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Filoviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices Ebola Virus Like Particles (HA-EBOV) Zaire (Genebank: KJ660346.2) Summary Ebola Virus like particles (HA-EBOV) Zaire (Genebank: KJ660346.2): A novel rapid hybrid alpha-pseudovirus for Ebolaviruses (EBOV) (HA-EBOV) from the Zaire strain that are available for your initial testing. These pseudoviruses are BSL2 safe and ready to use for studying viral entry. HAEBOV particles are pseudoviruses assembled from the structural proteins of the filovirus glycoprotein (GP), VP40 matrix protein, and the Nucleoprotein (NP) and package an alphaviral vector for reporter gene expression. The alpha-pseudoviruses are single-cycle viruses with self-replicating RNA for rapid quantification of neutralizing antibodies and entry-inhibiting drugs. Formulation & Storage: Available upon request Store at -80°C. Notes & Usage Guidelines: Size: 1X concentrated 25 x 200 µL ~100 wells-96 well plate Reporter: Available with Firefly luciferase, GFP, or RFP Virus-like particles (VLP’s) expressing recombinant GP (Glycoprotein), N (Nucleoporin), and PV40 matrix protein structural proteins This Ebola Virus like particles is intended for research use only, not for human, therapeutic, or diagnostic applications. Certificate of analysis: A hardcopy of the datasheet is sent along with the products. Please refer to it for detailed information. Overview PRODUCT NAME Ebola Virus like particles (HA-EBOV) Zaire (Genebank: KJ660346.2) PRODUCT TARGET EBOV Virus like particle PRODUCT ABBREVIATION EBOV VLP PATHOGEN STRAIN Zaire EBOV KJ660346.2 TARGET PATHOGEN Ebola Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Filoviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-Cov2) (XBB.1.16) Summary SARS-CoV-2, Virus Like Particles (Ha-CoV2) (XBB.1.16): hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for XBB.1.16 strain. The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike T19I, Spike L24S, Spike 25-27del, Spike V83A, Spike G142D, Spike Del144-144, Spike H146Q, SpikeE180V, Spike Q183E, Spike V213E, Spike G252V, Spike G339H, Spike R346T, Spike L368I, Spike S371F, Spike S373P, Spike S375F, Spike T376A, Spike D405N, Spike R408S, Spike K417N, Spike N440K, Spike V445P, Spike G446S,Spike N460K, Spike S477N, Spike T478R, Spike E484A, Spike F486P, Spike F490S, Spike Q498R, Spike N501Y, Spike Y505H, Spike D614G, Spike H655Y, Spike N679K, Spike P681H, Spike N764K, Spike D796Y, Spike Q954H, Spike N969K Size: 25 X 200 µL ~100 wells-96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Intended for research use only, not for human, therapeutic, or diagnostic applications. Overview PRODUCT NAME SARS-CoV-2, Virus Like Particles (Ha-CoV2) (XBB.1.16) PRODUCT TARGET SARS-CoV-2 Virus-like particle PRODUCT ABBREVIATION SARS-CoV-2 VLP PATHOGEN STRAIN XBB.1.16 TARGET PATHOGEN SARS-CoV-2 Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices Rabbit Anti-Ebola Virus VP40 PAB Summary Affinity purified rabbit polyclonal antibody reactive to Ebola Virus VP40. The antibody detects VP40 in virus-like particles (VLP) and recombinant VP40 (rVP40) in Western Blot and ELISA. Formulation: Supplied in PBS in frozen format with no preservatives added. Storage: Store at +4°C for 2-3 weeks; -80°C for long-term Guidelines Clonality-Isotype: Polyclonal; N-A Host: Rabbit Applications ELISA: Assay-dependent dilution Western Blot: Assay-dependent dilution Immunogen- Target Pathogen: Peptide sequence specific to Ebola Virus (EBOV) VP40 matrix protein. Purification: Affinity purified Product Type: Polyclonal Antibody Pathogen Strain: Zaire Rabbit anti-Ebola Virus VP40 pAb; Intended for research use only, not for human, therapeutic, or diagnostic applications. Overview PRODUCT NAME Rabbit Anti-Ebola Virus VP40 pAb PRODUCT TARGET Ebola VP40 PRODUCT ABBREVIATION EBOV VP40 pAb PATHOGEN STRAIN Zaire TARGET PATHOGEN Ebola Virus PRODUCT CATEGORY Primary Antibodies, Filoviruses PRODUCT TYPE Polyclonal Antibody PURIFICATION Affinity purified EXPRESSION N-A APPLICATIONS ELISA, Western Blot Properties Form: Liquid Formulation-Storage: Supplied in PBS in frozen format with no preservatives added. Store at +4°C for 2-3 weeks; -80°C for long-term Clonality-Isotype: Polyclonal; N-A Concentration: Batch Dependent PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices Nipah Virus-Like Particles (Ha-NIV) Summary A novel rapid hybrid alpha-pseudovirus for Nipah virus (HA-NiV). HA-NiV particles are pseudoviruses assembled from the structural proteins of the Nipah virus, Fusion (F), Glycoprotein (G), Matrix (M), and Nucleocapsid (N) proteins and package an alphaviral vector for reporter gene expression. The alphapseudoviruses are single-cycle viruses with self-replicating RNA for rapid quantification of neutralizing antibodies and entry-inhibiting drugs. These pseudoviruses are BSL-2 safe and ready to use for studying viral entry. Formulation & Storage: Store at -80°C. Notes & Usage Guidelines: Size: 1X concentrated 25 x 200 µL ~100 wells-96 well plate Reporter: Available with Firefly luciferase, GFP, or RFP Applications Rapid NiV pseudovirus transduction of target cells for viral entry and functional studies Anti-NiV drug screening Anti-NiV neutralizing antibody screening Intended for research use only, not for human, therapeutic, or diagnostic applications. Overview PRODUCT NAME Nipah Virus-like particles (HA-NiV) PRODUCT TARGET NiV Virus-like particle PRODUCT ABBREVIATION NiV VLP PATHOGEN STRAIN Nipah Virus TARGET PATHOGEN Nipah Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Other Viruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-Cov2) (XBB.1.5) Summary SARS-CoV-2, Virus Like Particles (Ha-CoV2) (XBB.1.5): hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for XBB.1.5 strain. The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle Spike Mutations: Spike T19I, Spike L24S, Spike del25-27, Spike V83A, Spike G142D,Spike del144-144, Spike H146Q, Spike Q183E, Spike V213E, Spike G252V, Spike G339H, Spike R346T, Spike L368I, Spike S371F, Spike S373P, Spike S375F, Spike T376A, Spike D405N, Spike R408S, Spike K417N,Spike N440K, Spike V445P, Spike G446S, Spike N460K, Spike S477N, Spike T478K, Spike E484A, Spike F486P, Spike F490S, Spike Q498R, Spike N501Y, Spike Y505H, Spike D614G, Spike H655Y, Spike N679K, Spike P681H, Spike N764K, Spike D796Y, Spike Q954H, Spike N969K Size: 25 X 200 µL ~100 wells-96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Overview PRODUCT NAME SARS-CoV-2, Virus Like Particles (Ha-CoV2) (XBB.1.5) PRODUCT TARGET SARS-CoV-2 Virus-like particle PRODUCT ABBREVIATION SARS-CoV-2 VLP PATHOGEN STRAIN XBB.1.5 TARGET PATHOGEN SARS-CoV-2 Virus PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Coronaviruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices Rabbit Anti-Ebola Virus NP PAB Summary Rabbit anti-Ebola Virus NP pAb or affinity purified rabbit polyclonal antibody reactive to EBOV NP. The antibody detects NP in virus-like particles (VLP) in Western blot and ELISA. Immunogen- Target Pathogen: Peptide sequence specific to Ebola virus (EBOV) Nucleocapsid Protein (NP). Formulation: Supplied in PBS in frozen format with no preservatives added. Storage: Store at +4°C for 2-3 weeks; -80°C for long-term Clonality-Isotype: Polyclonal; N-A Host: Rabbit Applications: ELISA: Assay-dependent dilution Western Blot: Assay-dependent dilution Intended for research use only, not for human, therapeutic, or diagnostic applications. Overview PRODUCT NAME Rabbit anti-Ebola Virus NP pAb PRODUCT TARGET Ebola nucleocapsid protein PRODUCT ABBREVIATION EBOV NP pAb PATHOGEN STRAIN Zaire TARGET PATHOGEN Ebola Virus PRODUCT CATEGORY Primary Antibodies, Filoviruses PRODUCT TYPE Polyclonal Antibody PURIFICATION Affinity purified EXPRESSION N-A APPLICATIONS ELISA, Western Blot Properties Form: Liquid Formulation-Storage: Supplied in PBS in frozen format with no preservatives added. Store at +4°C for 2-3 weeks; -80°C for long-term Clonality-Isotype: Polyclonal; N-A Concentration: Batch Dependent PSTG Supplies is an authorized distributor of IBT Bioservices products.

IBT Bioservices HIV Virus Like Particle (Human Immunodeficiency Virus) Summary HIV Virus like particle (VLP’s) expressing recombinant structural proteins Safe for use in BSL-2 facilities. Formulation & Storage: Store at -80°C. Notes & Usage Guidelines: Size: 1X concentrated 25 x 200 µL ~100 wells-96 well plate Reporter: Available with Firefly luciferase, GFP, or RFP Intended for research use only, not for human, therapeutic, or diagnostic applications. Certificate of analysis: A hardcopy of datasheet is sent along with the products. Please refer to it for detailed information. Overview PRODUCT NAME HIV Virus like particle (Human Immunodeficiency Virus) PRODUCT TARGET HIV Virus like particle PRODUCT ABBREVIATION HIV VLP PATHOGEN STRAIN Human Immunodeficiency Virus TARGET PATHOGEN HIV PRODUCT CATEGORY Pseudovirus, Virus Like Particles, Other Viruses PRODUCT TYPE Virus like particles Properties Form: Liquid Formulation: Available upon request Storage: -80°C Concentration: 1X Concentrated PSTG Supplies is an authorized distributor of IBT Bioservices products.